14:27 , Jun 29, 2018 |  BC Week In Review  |  Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on solid tumor indications where it sees larger market...
20:59 , Jun 25, 2018 |  BC Extra  |  Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL), including the withdrawal of a resubmitted MAA, to focus instead on...
17:13 , Dec 14, 2017 |  BC Week In Review  |  Clinical News

Erytech's Graspa misses in Phase IIb AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia (AML) in patients ineligible for...
23:44 , Dec 8, 2017 |  BC Extra  |  Clinical News

Erytech sinks after Graspa miss in AML study

Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase missed the primary endpoint in a Phase IIb trial to treat newly diagnosed acute myelogenous leukemia in...
19:43 , Nov 17, 2017 |  BC Week In Review  |  Financial News

Erytech raises $125M, lists on NASDAQ

Cancer company Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) raised $143.8 million in a follow-on on NASDAQ and concurrent private placement. The company raised $125.3 million through the sale of 5.4 million ADSs at $23.26 in its...
00:04 , Nov 15, 2017 |  BC Extra  |  Financial News

Erytech raises $125M, lists on NASDAQ

On Nov. 10, Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) raised $125 million in a follow-on on NASDAQ and concurrent private placement. The company raised $109 million through the sale of 4.7 million ADSs at $23.26 in...
18:50 , Oct 27, 2017 |  BC Week In Review  |  Clinical News

Erytech reports additional Phase IIb data for eryaspase in pancreatic cancer

In September, Erytech Pharma S.A. (Euronext:ERYP) reported additional data from a Phase IIb trial to treat progressive metastatic pancreatic cancer showing that second-line treatment with eryaspase (Graspa, ERY-ASP, ERY001) plus standard of care (SOC) gemcitabine...
19:46 , Oct 13, 2017 |  BC Week In Review  |  Financial News

Erytech seeking NASDAQ listing

On Oct. 6 after trading hours, Erytech Pharma S.A. (Euronext:ERYP) proposed to raise up to $100 million in a NASDAQ listing and concurrent private placement. Jefferies, Cowen, Oddo BHF and JMP Securities are the listing's...
23:41 , Oct 9, 2017 |  BC Extra  |  Financial News

Erytech seeking NASDAQ listing

Erytech Pharma S.A. (Euronext:ERYP) proposed to raise up to $100 million in a NASDAQ listing and concurrent private placement. Jefferies, Cowen, Oddo BHF and JMP Securities are the listing's underwriters. The company will offer the...
00:20 , Jul 8, 2017 |  BioCentury  |  Finance

A clinical quarter

Buysiders will find themselves digesting at least 23 Phase III data readouts in the next quarter, two of which could provide clarity on increasingly competitive markets in lung cancer and hemophilia. The third quarter is...